NDAINJECTIONINJECTABLE
Approved
May 1982
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
FUROSEMIDE (furosemide) by Pfizer is henle. First approved in 1982.
Drug data last refreshed 14h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Furosemide is a loop diuretic that blocks sodium and chloride reabsorption in the ascending limb of the Loop of Henle, making it one of the most potent diuretics available. It is indicated for heart failure and hypertension, working through a unique mechanism independent of carbonic anhydrase or aldosterone inhibition. This injectable formulation has been a standard of care for acute decompensated heart failure and resistant hypertension for over 40 years.
LOE Approaching
As an established drug approaching loss of exclusivity with moderate competitive pressure (30%), the brand team is likely focused on generic transition planning and defensive strategies rather than growth initiatives.
Mechanism of Action
Henle. The high degree of efficacy is largely due to this unique site of action. The action on the distal tubule is independent of any inhibitory effect on carbonic anhydrase and aldosterone.
Pharmacologic Class:
Loop Diuretic
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Bumetanide vs. Furosemide in Cirrhosis
Started May 2026
500 enrolled
Cirrhosis
A Clinical Study of the Effect of MK-2828 on Rosuvastatin or Furosemide in Healthy People (MK-2828-005)
Started Mar 2026
39 enrolled
Healthy
Study to Compare Bioavailability and Pharmacokinetics of a Novel Furosemide Regimen Administered Subcutaneously Versus the Same Dose (80 mg) Administered Intravenously in Healthy Volunteers
Started Feb 2026
16 enrolled
Healthy
A Study in Healthy Men to Test Whether Zongertinib Influences the Amount of 4 Other Medicines (Dabigatran, Rosuvastatin, Metformin, and Furosemide) in the Blood
Started Aug 2024
32 enrolled
Healthy
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 as Well as the Impact of AZD4144 on the Pharmacokinetics of Rosuvastatin and Furosemide in Healthy Participants
Started Jul 2024
91 enrolled
Healthy Participants
Worked on FUROSEMIDE at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.